FDA Awards Fast Track Designation to LBS-007 for Acute Myeloid Leukemia
LBS-007 receives fast track status from the FDA for use in patients with acute myeloid leukemia.
LBS-007 receives fast track status from the FDA for use in patients with acute myeloid leukemia.
Pirtobrutinib improved outcomes over investigator’s choice of treatment in patients with CLL/SLL previously treated with a cBTKi.
Early Career Award | Cancer Discovery | American Association for Cancer Research .aacrcontent .banner{ width: 100% margin: -20px; } .aacrcontent .banner-sm{ display: none; } .right{float:…
Liquid biopsy has received tremendous attention as a non-invasive approach for detecting and tracking cancer. Here, we discuss the latest work on circulating tumor DNA…
Adding pembrolizumab to THP improved pCR rates in patients with HER2-positive breast cancer in the phase 2 NeoHIP trial.
Cosibelimab is now FDA approved for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma that is not eligible for curative…
Chest wall irradiation after mastectomy did not improve 10-year overall survival in patients with intermediate-risk breast cancer.
ATTR amyloidosis (ATTR) is a progressive disease, which means it can worsen over time. Early diagnosis is crucial, talk with your doctor today.
Findings from the ZEST trial highlight the potential of ctDNA surveillance in breast cancer management. Discover the role of Niraparib in enhancing disease-free survival.
Nature Reviews Cancer – Conventional chemotherapy has successfully cured millions of patients with cancer, yet the mechanisms of action for this remain unclear. In this…
Nature Reviews Cancer – Patient-derived xenograft (PDX) models are valuable surrogates for drug testing in precision oncology. In this Review, Welm and colleagues outline the…